James Van Der Beek, who was suffering from colorectal cancer, was a spokesperson for the company and its Shield blood test.

Guardant Health stock is back in focus after a major institutional investor reduced its position by nearly one-third. Principal Financial Group lowered its holdings during the latest quarter, while ...

A GoFundMe for Austinite actor James Van Der Beek's family surpassed $1.5 million after his death. Guardant Health donated ...

Patient and Public Health Groups Invited to Apply for Up to 100 Shield Colorectal Cancer Blood Tests to Support Community Screening Events and Educational Outreach in March PALO ALTO, Calif.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated exchange ...

New Guardant Reveal offering provides oncologists with tissue-free solution to monitor treatment response and detect early disease progression with unprecedented speed and sensitivity Reveal is ...

Preliminary unaudited free cash flow was approximately negative $84 million for the fourth quarter of 2024, and approximately negative $275 million for the full year 2024. Cash, cash equivalents, ...

Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its upsized offering of $350.0 million aggregate principal amount of 0% ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a ...

Total revenue of approximately $981 million, an increase of 33% Reported approximately 276,000 oncology tests, an increase of 34% Reported approximately 87,000 Shield screening tests “2025 was a ...